Vivoryon Therapeutics NV - ESG Rating & Company Profile powered by AI
Jump to the bottom of this page for potential risks for Vivoryon Therapeutics NV based on industry, geography and size. This webpage of Vivoryon Therapeutics NV is prepared by All Street Sevva using leading NLP. This page contains a questions and answers section on Vivoryon Therapeutics NV.
Vivoryon Therapeutics NV in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.0; made up of an environmental score of 3.2, social score of 4.8 and governance score of 4.0.
4.0
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 1412 | Vallon Pharmaceuticals Inc | 4.1 | High |
| 1412 | Vectura Group PLC | 4.1 | High |
| 1443 | Vivoryon Therapeutics NV | 4.0 | High |
| 1443 | Adaptive Biotechnologies Corp | 4.0 | High |
| 1443 | Ascletis Pharma Inc | 4.0 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Vivoryon Therapeutics NV have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Vivoryon Therapeutics NV disclose current and historical energy intensity?
Sign up for free to unlockDoes Vivoryon Therapeutics NV report the average age of the workforce?
Sign up for free to unlockDoes Vivoryon Therapeutics NV reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Vivoryon Therapeutics NV disclose its ethnicity pay gap?
Sign up for free to unlockDoes Vivoryon Therapeutics NV disclose cybersecurity risks?
Sign up for free to unlockDoes Vivoryon Therapeutics NV offer flexible work?
Sign up for free to unlockDoes Vivoryon Therapeutics NV have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Vivoryon Therapeutics NV disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Vivoryon Therapeutics NV conduct supply chain audits?
Sign up for free to unlockDoes Vivoryon Therapeutics NV disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Vivoryon Therapeutics NV conduct 360 degree staff reviews?
Sign up for free to unlockDoes Vivoryon Therapeutics NV disclose the individual responsible for D&I?
Sign up for free to unlockDoes Vivoryon Therapeutics NV disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Vivoryon Therapeutics NV disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Vivoryon Therapeutics NV disclose water use targets?
Sign up for free to unlockDoes Vivoryon Therapeutics NV have careers partnerships with academic institutions?
Sign up for free to unlockDid Vivoryon Therapeutics NV have a product recall in the last two years?
Sign up for free to unlockDoes Vivoryon Therapeutics NV disclose incidents of discrimination?
Sign up for free to unlockDoes Vivoryon Therapeutics NV allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Vivoryon Therapeutics NV issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Vivoryon Therapeutics NV disclose parental leave metrics?
Sign up for free to unlockDoes Vivoryon Therapeutics NV disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Vivoryon Therapeutics NV disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Vivoryon Therapeutics NV disclose the pay ratio of women to men?
Sign up for free to unlockDoes Vivoryon Therapeutics NV support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Vivoryon Therapeutics NV disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Vivoryon Therapeutics NV reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Vivoryon Therapeutics NV involved in embryonic stem cell research?
Sign up for free to unlockDoes Vivoryon Therapeutics NV disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Vivoryon Therapeutics NV disclose its waste policy?
Sign up for free to unlockDoes Vivoryon Therapeutics NV report according to TCFD requirements?
Sign up for free to unlockDoes Vivoryon Therapeutics NV disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Vivoryon Therapeutics NV disclose energy use targets?
Sign up for free to unlockDoes Vivoryon Therapeutics NV disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Vivoryon Therapeutics NV have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Vivoryon Therapeutics NV
These potential risks are based on the size, segment and geographies of the company.
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development product is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics N.V. has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.